Although selumetinib was approved for neurofibromas in many countries including FDA, one of potential MEK inhibitors and treatment options, selumetinib still has been investigated various solid tumors such as colorectal cancer, lung cancer, and gastric cancers including EC. Here, MAP2K7 is linked to gastric cancer.